Medi-Tate Ltd.

What Medi-Tate Ltd. does

Medi-Tate Ltd. is an Israeli medical device company headquartered in Hadera, founded in 2007, that develops and commercializes the iTind (Temporarily Implanted Nitinol Device) procedure for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). The company's core technology is a small nitinol device that is temporarily placed inside the prostate, where it applies gentle, sustained pressure over a 5-7 day period to create channels that reduce obstruction and improve urine flow; the device is then fully removed, leaving no permanent implant. The procedure is positioned as a minimally invasive alternative positioned between chronic BPH medication (e.g., daily alpha-blockers or 5-alpha-reductase inhibitors) and invasive surgery, with the value proposition centered on preserving urinary control, sexual function, and quality of life while requiring minimal recovery time. The product is administered by trained urologists in office-based or outpatient/ambulatory surgery settings, with patients discharged same-day and returning 5-7 days later for device removal.

The company's revenue model is hardware-based: the device is sold to urology practices and outpatient clinics where the procedure is performed. Go-to-market is dual-track, simultaneously targeting patients through a consumer-facing educational website (itind.com) with testimonials, a physician finder, and downloadable brochures, and healthcare providers through a separate medical-professional portal. Medi-Tate's primary customer segment is men aged 50 and older experiencing BPH-related urinary symptoms who want to avoid lifetime medication or invasive surgery. In the United States and Germany the product is marketed and distributed under the Olympus America brand, indicating a parent-subsidiary or licensing/distribution relationship that gives Medi-Tate access to Olympus's established urology sales infrastructure, physician training, and regulatory footprint rather than building these capabilities independently.

Name

Medi-Tate Ltd.

Legal name

Medi-Tate Ltd.

Website

https://medi-tate.com

Company type

Private

Founded year

2007

Operating status

Operating

Short description

Medi-Tate Ltd. is an Israeli medical device company that develops the iTind procedure, a temporarily implanted nitinol device used by urologists to reshape the prostate over 5-7 days and treat urinary symptoms from benign prostatic hyperplasia in men 50+, commercially distributed in the U.S. and Germany via Olympus America.

Ownership category

akta.pro rank

Product category

Urological Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Endourology & Minimally Invasive Urologic Surgery (HLAKAOAF)

akta.pro secondary industry

General Urology (HLAKAOAA)

Keywords

• Benign prostatic hyperplasia treatment
• Minimally invasive urology
• Temporary prostate implant
• Nitinol medical device
• Urological surgical devices

Headquarters

HQ city

Hadera

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: The iTind device is sold to healthcare providers (urologists, outpatient clinics) who perform the procedure. Revenue is generated through device sales to medical facilities where procedures are performed in doctor offices or outpatient settings.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Medi-Tate Ltd. develops and manufactures the iTind (Temporarily Implanted Nitinol Device), a minimally invasive medical device for treating lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). The nitinol device is placed inside the prostate and reshapes the tissue over 5-7 days to improve urine flow, after which it is completely removed, leaving no permanent implant. The device is commercialized in partnership with Olympus America and is performed by urologists in office or outpatient settings.

Product overview

Medi-Tate Ltd. offers the iTind (Temporarily Implanted Nitinol Device) procedure, a minimally invasive treatment for Benign Prostatic Hyperplasia (BPH). The core offering is the iTind Procedure, which involves temporarily implanting a nitinol device into the prostate for 5-7 days to reshape the prostate and improve urine flow, after which the device is completely removed. The product portfolio includes the core iTind Procedure along with supporting patient education materials including the Patient Brochure (available in English and Spanish), the BPH Symptom Checker questionnaire, and enrollment information for clinical studies targeting men 50+.

Differentiator

Problem solved

Functional benefit

Brands

• iTind: Temporary implantable nitinol device for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH)

Products and services

• iTind Procedure

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Olympus America (Parent Company)coreOEM/ Whitelabel/ Licensing PartnerThe iTind device is marketed and distributed by Olympus America under the Olympus corporate brand. The website is hosted at itind.com with Olympus branding throughout, indicating a parent-subsidiary or licensing distribution relationship where Olympus handles commercialization of the iTind technology.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Boston Scientific: Acquired NxThera and markets the Rezum System, a water-vapor thermal therapy device for BPH. Targets the same minimally invasive BPH patient segment with a similar outpatient, in-office procedure and represents iTind's primary clinical evidence comparator.
• Teleflex: Makes the Urolift System, a directly competing minimally invasive BPH device (permanent implants that retract prostate tissue). Operates in the same procedural setting (outpatient urology) and same patient population (men with LUTS secondary to BPH) as iTind, making it the closest head-to-head competitor.
• PROCEPT BioRobotics: Markets the AquaBeam (Aquablation) robot-assisted waterjet system for BPH. Competes for the same robotic and minimally invasive BPH surgical slot, especially in urology ORs seeking technology-forward treatment options.

Emerging players

• AngioDynamics: Offers the NanoKnife irreversible electroporation system, which has been studied for prostate applications including focal BPH treatment. Operates adjacent to iTind in the interventional urology space with overlapping minimally invasive outpatient positioning.
• SRS Medical Systems: Developer of the Tind device (ForeLoop/Prolyx) earlier-generation temporary implantable prostatic devices sharing conceptual lineage with iTind. Closely adjacent niche competitor in the temporary-implant BPH category, though smaller scale and less commercial traction.
• Sonablate (SonaCare Medical): Makes HIFU (high-intensity focused ultrasound) platforms historically used for prostate ablation and increasingly for BPH-related applications. Competes in the tissue-targeted BPH treatment space but with a different energy modality than nitinol mechanical reshaping.
• HistoSonics: Developer of a histotripsy platform (non-thermal focused ultrasound) being explored for prostate applications including BPH. Represents an emerging non-thermal mechanical tissue-remodeling alternative that overlaps conceptually with iTind's "tissue reshaping without permanent implant" positioning.

Broad incumbents

• Karl Storz SE & Co. KG: Long-established German endoscopy and urology equipment manufacturer with deep installed base in urology ORs and outpatient settings globally. Represents the broader incumbent channel against which Olympus (with iTind) competes for urology budgets and capital placements.
• Johnson & Johnson (MedTech / Cerenovus): Operates broadly across urology and interventional devices with potential to enter or expand within BPH via its MedTech platform. A scaled incumbent that could either compete with or seek to acquire assets like iTind in the minimally invasive BPH category.
• Olympus Corporation: Global endoscopy and urology device conglomerate that markets and distributes the iTind product in the U.S. (and likely other geographies). Operates broadly across urology, endoscopy, and surgical specialties, with iTind representing one specialized asset within a much larger portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medi-Tate Ltd.